secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2021-08-10T23:59:59+00:00
Accession:  0001823239-21-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai Q2 revenue up 364% to $217.8M, raises FY guidance to $745-770M; selling Vector for $124M
--------------------------------------------------------------------------------

- Q2 revenue $217.8M (+364% YoY); net income $134.3M vs $1.4M; Adj. EBITDA $164.7M vs $17.5M.
- Nucleic Acid Production revenue $192.5M (+532.8% YoY) driven by CleanCap demand for COVID-19 vaccines.
- Divested Protein Detection segment (Vector) for $124M cash to Thompson Street Capital Partners; close expected Q3 2021.
- 2021 revenue guidance raised to $745-770M from prior; reflects robust demand for Nucleic Acid Production.
- Facility expansions: new San Diego site to boost mRNA capacity; Biologic Safety Testing moving to larger Leland, NC site.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323921000018/0001823239-21-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323921000018/mrvi-20210805.htm
  HTML page:      https://secwatch.observer/filing/0001823239-21-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer